Revenue in Q1 2024 increased 26%, driven by Mounjaro, Zepbound, Verzenio and Jardiance. Pipeline progress included positive results from two Phase 3 trials of.
First Quarter 2024 Highlights: Total revenue increased 7% to $153.6 million Lindblad segment available guest nights increased 3% Lindblad segment net yield per.
/PRNewswire/ Progressive Care Inc. (OTCQB: RXMD) ("Progressive Care" or the "Company"), a personalized healthcare services and technology provider, today.
Creatd announces revenue guidance of $2M for Fiscal Year 2023, with expectations for significant growth in FY2024, subject to its upcoming strategic plan.